S&P 500   3,324.21 (+0.54%)
DOW   27,124.82 (+1.10%)
QQQ   270.89 (+0.19%)
AAPL   437.35 (-0.30%)
MSFT   213.34 (+0.02%)
FB   250.47 (+0.25%)
GOOGL   1,482.52 (+0.63%)
AMZN   3,193.80 (+1.75%)
NVDA   450.57 (+0.33%)
CGC   19.28 (-0.21%)
BABA   265.21 (+1.15%)
TSLA   1,484.48 (-0.17%)
MU   50.88 (-0.82%)
GE   6.18 (+0.65%)
AMD   84.92 (-0.14%)
T   29.82 (-0.63%)
F   6.97 (+1.60%)
ACB   10.76 (+0.28%)
GILD   69.49 (-1.96%)
NFLX   504.95 (-0.92%)
DIS   128.34 (+9.42%)
BAC   25.29 (+1.12%)
BA   174.12 (+5.48%)
S&P 500   3,324.21 (+0.54%)
DOW   27,124.82 (+1.10%)
QQQ   270.89 (+0.19%)
AAPL   437.35 (-0.30%)
MSFT   213.34 (+0.02%)
FB   250.47 (+0.25%)
GOOGL   1,482.52 (+0.63%)
AMZN   3,193.80 (+1.75%)
NVDA   450.57 (+0.33%)
CGC   19.28 (-0.21%)
BABA   265.21 (+1.15%)
TSLA   1,484.48 (-0.17%)
MU   50.88 (-0.82%)
GE   6.18 (+0.65%)
AMD   84.92 (-0.14%)
T   29.82 (-0.63%)
F   6.97 (+1.60%)
ACB   10.76 (+0.28%)
GILD   69.49 (-1.96%)
NFLX   504.95 (-0.92%)
DIS   128.34 (+9.42%)
BAC   25.29 (+1.12%)
BA   174.12 (+5.48%)
S&P 500   3,324.21 (+0.54%)
DOW   27,124.82 (+1.10%)
QQQ   270.89 (+0.19%)
AAPL   437.35 (-0.30%)
MSFT   213.34 (+0.02%)
FB   250.47 (+0.25%)
GOOGL   1,482.52 (+0.63%)
AMZN   3,193.80 (+1.75%)
NVDA   450.57 (+0.33%)
CGC   19.28 (-0.21%)
BABA   265.21 (+1.15%)
TSLA   1,484.48 (-0.17%)
MU   50.88 (-0.82%)
GE   6.18 (+0.65%)
AMD   84.92 (-0.14%)
T   29.82 (-0.63%)
F   6.97 (+1.60%)
ACB   10.76 (+0.28%)
GILD   69.49 (-1.96%)
NFLX   504.95 (-0.92%)
DIS   128.34 (+9.42%)
BAC   25.29 (+1.12%)
BA   174.12 (+5.48%)
S&P 500   3,324.21 (+0.54%)
DOW   27,124.82 (+1.10%)
QQQ   270.89 (+0.19%)
AAPL   437.35 (-0.30%)
MSFT   213.34 (+0.02%)
FB   250.47 (+0.25%)
GOOGL   1,482.52 (+0.63%)
AMZN   3,193.80 (+1.75%)
NVDA   450.57 (+0.33%)
CGC   19.28 (-0.21%)
BABA   265.21 (+1.15%)
TSLA   1,484.48 (-0.17%)
MU   50.88 (-0.82%)
GE   6.18 (+0.65%)
AMD   84.92 (-0.14%)
T   29.82 (-0.63%)
F   6.97 (+1.60%)
ACB   10.76 (+0.28%)
GILD   69.49 (-1.96%)
NFLX   504.95 (-0.92%)
DIS   128.34 (+9.42%)
BAC   25.29 (+1.12%)
BA   174.12 (+5.48%)
Log in

OTCMKTS:RLMDRelmada Therapeutics News Headlines

$36.69
-0.70 (-1.87 %)
(As of 08/5/2020 12:59 PM ET)
Add
Compare
Today's Range
$36.00
Now: $36.69
$37.80
50-Day Range
$36.37
MA: $43.09
$49.98
52-Week Range
$8.08
Now: $36.69
$54.00
Volume36,625 shs
Average Volume161,538 shs
Market Capitalization$557.54 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Relmada Therapeutics (OTCMKTS RLMD) News Headlines

Source:
DateHeadline
Relmada Therapeutics Inc (OTCMKTS:RLMD) Director Charles J. Casamento Sells 3,000 SharesRelmada Therapeutics Inc (OTCMKTS:RLMD) Director Charles J. Casamento Sells 3,000 Shares
americanbankingnews.com - August 4 at 5:16 PM
Relmada Therapeutics (OTCMKTS:RLMD) Shares Up 6.6%Relmada Therapeutics (OTCMKTS:RLMD) Shares Up 6.6%
americanbankingnews.com - August 3 at 8:48 PM
Relmada Therapeutics (OTCMKTS:RLMD) Share Price Crosses Below 50 Day Moving Average of $43.88Relmada Therapeutics (OTCMKTS:RLMD) Share Price Crosses Below 50 Day Moving Average of $43.88
www.americanbankingnews.com - August 1 at 5:51 AM
Oppenheimer Comments on Relmada Therapeutics Incs Q2 2020 Earnings (OTCMKTS:RLMD)Oppenheimer Comments on Relmada Therapeutics Inc's Q2 2020 Earnings (OTCMKTS:RLMD)
www.americanbankingnews.com - July 16 at 6:24 AM
Relmada Therapeutics (OTCMKTS:RLMD) Receives New Coverage from Analysts at OppenheimerRelmada Therapeutics (OTCMKTS:RLMD) Receives New Coverage from Analysts at Oppenheimer
www.americanbankingnews.com - July 13 at 5:38 PM
Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
finance.yahoo.com - July 13 at 1:05 PM
Relmada Therapeutics Inc (OTCMKTS:RLMD) Receives Consensus Recommendation of "Buy" from BrokeragesRelmada Therapeutics Inc (OTCMKTS:RLMD) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 13 at 3:30 AM
Hedge Funds Are Nibbling On Relmada Therapeutics, Inc. (RLMD)Hedge Funds Are Nibbling On Relmada Therapeutics, Inc. (RLMD)
finance.yahoo.com - June 24 at 5:57 PM
BRIEF-Relmada Therapeutics Announces Notice Of Allowance For Patent In CanadaBRIEF-Relmada Therapeutics Announces Notice Of Allowance For Patent In Canada
www.reuters.com - June 23 at 10:24 AM
Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare ConferenceRelmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
finance.yahoo.com - May 29 at 9:47 AM
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of OperationsRelmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
finance.yahoo.com - May 26 at 8:41 AM
SunTrust sees 90% upside in Relmada Therapeutics in premarket analyst actionSunTrust sees 90% upside in Relmada Therapeutics in premarket analyst action
seekingalpha.com - May 4 at 9:25 AM
Goldman Sachs: 2 Stocks That Could Climb Over 60%Goldman Sachs: 2 Stocks That Could Climb Over 60%
finance.yahoo.com - April 27 at 9:48 AM
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and SafetyRelmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
finance.yahoo.com - March 31 at 11:18 AM
Should You Take Comfort From Insider Transactions At Relmada Therapeutics, Inc. (NASDAQ:RLMD)?Should You Take Comfort From Insider Transactions At Relmada Therapeutics, Inc. (NASDAQ:RLMD)?
finance.yahoo.com - March 28 at 12:03 PM
Relmada Therapeutics: A Promising Depression Focused Player For 2020Relmada Therapeutics: A Promising Depression Focused Player For 2020
seekingalpha.com - February 17 at 12:37 PM
Relmada Therapeutics Announces $6.9 Million Private PlacementRelmada Therapeutics Announces $6.9 Million Private Placement
www.bloomberg.com - February 14 at 10:58 PM
70 Biggest Movers From Yesterday70 Biggest Movers From Yesterday
www.msn.com - December 12 at 11:08 PM
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common StockSichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock
finance.yahoo.com - December 10 at 8:40 AM
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesRelmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - December 9 at 6:14 PM
AUPH Soars On Lupus Trial Results, ACAD On Watch, ALNA Trims WorkforceAUPH Soars On Lupus Trial Results, ACAD On Watch, ALNA Trims Workforce
www.nasdaq.com - December 5 at 12:03 AM
Alexander Capital, L.P. Congratulates Relmada Therapeutics, Inc. on Its $100 Million FinancingAlexander Capital, L.P. Congratulates Relmada Therapeutics, Inc. on Its $100 Million Financing
www.baystreet.ca - December 4 at 7:03 PM
Relmada Therapeutics Announces Pricing of Public Offering of Common StockRelmada Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - December 3 at 11:32 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - November 19 at 5:09 PM
Relmada Therapeutics, Inc. Rings the Opening BellRelmada Therapeutics, Inc. Rings the Opening Bell
www.nasdaq.com - October 28 at 5:47 PM
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
finance.yahoo.com - October 17 at 1:30 PM
BRIEF-Relmada Therapeutics Inc Announces Top-Line Results From REL-1017 Phase 2 Study In Individuals With Treatment Resistant DepressionBRIEF-Relmada Therapeutics Inc Announces Top-Line Results From REL-1017 Phase 2 Study In Individuals With Treatment Resistant Depression
www.msn.com - October 15 at 10:30 PM
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant DepressionRelmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
finance.yahoo.com - October 15 at 12:29 PM
Relmada Therapeutics stock rockets 137% on positive trial of depression treatmentRelmada Therapeutics stock rockets 137% on positive trial of depression treatment
finance.yahoo.com - October 15 at 12:29 PM
Relmada Therapeutics to Announce Results of Phase...Relmada Therapeutics to Announce Results of Phase...
www.benzinga.com - October 14 at 6:44 PM
Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital MarketRelmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
finance.yahoo.com - October 10 at 8:55 AM
Relmada Therapeutics announces 1-for-4 reverse stock split for proposed uplisting to NASDAQRelmada Therapeutics announces 1-for-4 reverse stock split for proposed uplisting to NASDAQ
seekingalpha.com - September 27 at 4:40 PM
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital MarketRelmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
finance.yahoo.com - September 27 at 4:40 PM
Collision With Reality Sends Abeona Stock Spiraling LowerCollision With Reality Sends Abeona Stock Spiraling Lower
seekingalpha.com - July 31 at 10:11 AM
Relmada advancing depression candidate REL-1017, mid-stage data readout this quarterRelmada advancing depression candidate REL-1017, mid-stage data readout this quarter
seekingalpha.com - July 29 at 6:44 PM
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant DepressionRelmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
finance.yahoo.com - July 29 at 8:27 AM
Relmada Therapeutics to Present at LD Micro Invitational Conference in Los AngelesRelmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles
finance.yahoo.com - June 3 at 9:41 AM
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology MeetingRelmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
finance.yahoo.com - May 31 at 9:50 AM
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies ResultsRelmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
finance.yahoo.com - April 16 at 10:43 AM
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical OperationsGina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
finance.yahoo.com - April 3 at 6:33 PM
Vistgen And Relmada: Competitors In Depression TreatmentVistgen And Relmada: Competitors In Depression Treatment
seekingalpha.com - March 20 at 6:14 PM
Relmada Therapeutics IncRelmada Therapeutics Inc
www.bloomberg.com - March 19 at 10:05 AM
Relmada Therapeutics to Present at Biotech Showcase 2019Relmada Therapeutics to Present at Biotech Showcase 2019
finance.yahoo.com - January 2 at 9:30 AM
This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.